Related Experiment Video
Updated: Mar 17, 2026
09:22
Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
Published on: April 2, 2017
14.8K
Akt: A Therapeutic Target in Hepatic Ischemia-Reperfusion Injury
Stephen M Covington1, Laura D Bauler2, Luis H Toledo-Pereyra2
1a Michigan State University College of Osteopathic Medicine , East Lansing, Michigan , USA.
Summary
Therapeutic manipulation of the Akt pathway can reduce liver damage from ischemia/reperfusion (I/R) injury during transplantation. Activating Akt shows promise in protecting hepatocytes and warrants further clinical trials.
Area of Science:
- Transplantation immunology
- Molecular biology
- Hepatology
Background:
- Liver transplantation is common, but ischemia/reperfusion (I/R) injury causes significant post-transplant dysfunction.
- The serine/threonine kinase Akt is activated during I/R injury and promotes cellular survival.
- Targeting the Akt pathway offers a potential strategy to mitigate hepatic I/R injury.
Purpose of the Study:
- This review comprehensively examines therapeutic strategies targeting the Akt pathway to reduce hepatic I/R injury.
- It aims to highlight recent advances in manipulating Akt for therapeutic benefit in liver transplantation.
Main Methods:
- An extensive literature review was conducted using Scopus and PubMed databases.
- Seventy-five articles were analyzed, combining search terms like "hepatic ischemia/reperfusion injury" and "Akt/PKB."
- Key concepts explored included preconditioning, postconditioning, and pharmacological interventions.
Main Results:
- Four primary methods to reduce I/R injury were identified: hepatic preconditioning, postconditioning, pharmacological interventions, and miRNA/gene therapy.
- Therapeutic efficacy was confirmed by reductions in serum alanine aminotransferase levels and improved liver histology.
- Phosphorylation of downstream mediators validated the protective effects mediated by Akt activation.
Conclusions:
- Akt activation consistently reduces hepatocyte damage, as evidenced by biochemical and histological markers.
- Combining these Akt-targeting therapies may improve outcomes for liver transplant recipients.
- Further clinical trials are needed to validate these findings in human subjects.
